Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells

[1]  A. Howell,et al.  Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer , 2011, Journal of Medical Genetics.

[2]  Jae Hyun Kim,et al.  An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer , 2011, British Journal of Cancer.

[3]  J. Wrana,et al.  Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. , 2011, Cancer research.

[4]  M. van Engeland,et al.  Characteristics of triple-negative breast cancer , 2010, Journal of Cancer Research and Clinical Oncology.

[5]  Jorge S Reis-Filho,et al.  Triple-negative breast cancer. , 2010, The New England journal of medicine.

[6]  Edith A Perez,et al.  Treatment options for patients with triple-negative breast cancer , 2010, Journal of hematology & oncology.

[7]  Ricardo H Álvarez,et al.  Present and future evolution of advanced breast cancer therapy , 2010, Breast Cancer Research.

[8]  J. Moffat,et al.  Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens , 2010, EMBO molecular medicine.

[9]  Yu Shyr,et al.  RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells , 2010, Breast Cancer Research.

[10]  E. Prochownik,et al.  Permanently Blocked Stem Cells Derived From Breast Cancer Cell Lines , 2010, Stem cells.

[11]  C. Eaves,et al.  Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. , 2010, Cancer research.

[12]  Christian Sillaber,et al.  Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. , 2010, Cancer research.

[13]  Youwei Zhang,et al.  Targeting the checkpoint kinase Chk1 in cancer therapy , 2010, Cell cycle.

[14]  Y. Degenhardt,et al.  Targeting Polo-like Kinase in Cancer Therapy , 2010, Clinical Cancer Research.

[15]  A. Ray,et al.  Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics , 2010, Expert opinion on investigational drugs.

[16]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[17]  T. Triche,et al.  Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas , 2009, Molecular Cancer Therapeutics.

[18]  John Quackenbush,et al.  Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor–Negative Breast Cancer , 2009, Clinical Cancer Research.

[19]  Justin C. Grindley,et al.  Tumour-initiating cells: challenges and opportunities for anticancer drug discovery , 2009, Nature Reviews Drug Discovery.

[20]  D. Birnbaum,et al.  Breast cancer stem cells: tools and models to rely on , 2009, BMC Cancer.

[21]  M. Harrison,et al.  Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. , 2009, Clinical advances in hematology & oncology : H&O.

[22]  D. Coradini,et al.  The Controversial Clinicobiological Role of Breast Cancer Stem Cells , 2009, Journal of oncology.

[23]  Debra L Winkeljohn.  Triple-negative breast cancer. , 2008, Clinical journal of oncology nursing.

[24]  L. Goldstein.  Experience in Phase I Trials and an Upcoming Phase II Study with uPA Inhibitors in Metastatic Breast Cancer , 2008, Breast Care.

[25]  P. Bevan,et al.  The Role of uPA and uPA Inhibitors in Breast Cancer , 2008, Breast Care.

[26]  M. Malumbres,et al.  Emerging cancer therapeutic opportunities by inhibiting mitotic kinases. , 2008, Current opinion in pharmacology.

[27]  O. Ben‐Izhak,et al.  Over-expression of Skp2 is associated with resistance to preoperative doxorubicin-based chemotherapy in primary breast cancer , 2008, Breast Cancer Research.

[28]  M. Wicha.  Cancer stem cell heterogeneity in hereditary breast cancer , 2008, Breast Cancer Research.

[29]  Charlotte Kuperwasser,et al.  Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy , 2008, Breast Cancer Research.

[30]  T. Nielsen,et al.  Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy , 2007, Breast Cancer Research.

[31]  S. Dunn,et al.  The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) Prevents Y-Box Binding Protein-1 from Inducing Epidermal Growth Factor Receptor , 2007, Molecular Pharmacology.

[32]  K. Strebhardt,et al.  Rational combinations of siRNAs targeting Plk1 with breast cancer drugs , 2007, Oncogene.

[33]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[34]  A. Ashworth,et al.  Utilizing RNA interference to enhance cancer drug discovery , 2007, Nature Reviews Drug Discovery.

[35]  Péter Lénárt,et al.  BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo , 2007, Current Biology.

[36]  M. Malumbres,et al.  A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. , 2006, Carcinogenesis.

[37]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[38]  Harikrishna Nakshatri,et al.  CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis , 2006, Breast Cancer Research.

[39]  A. Giuliano,et al.  Most Early Disseminated Cancer Cells Detected in Bone Marrow of Breast Cancer Patients Have a Putative Breast Cancer Stem Cell Phenotype , 2006, Clinical Cancer Research.

[40]  E. Yorida,et al.  HER-2 Suppression of the Epidermal Growth Factor Receptor and Disruption of the Y-Box Binding Protein-1 Results in Updated , 2006 .

[41]  A. Ullrich,et al.  Targeting polo-like kinase 1 for cancer therapy , 2006, Nature Reviews Cancer.

[42]  M. Lei,et al.  Normal Cells, but Not Cancer Cells, Survive Severe Plk1 Depletion , 2006, Molecular and Cellular Biology.

[43]  T. Utsunomiya,et al.  Significance of skp2 expression in primary breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  Jeffrey P. MacKeigan,et al.  Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance , 2005, Nature Cell Biology.

[45]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[46]  Maria Athelogou,et al.  Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  S. Ramaswamy,et al.  Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. , 2002, The Journal of clinical investigation.

[48]  R. Kaufmann,et al.  Expression of polo‐like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease , 2002, Journal of cutaneous pathology.

[49]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[50]  Christine Solbach,et al.  Identification of high risk breast-cancer patients by gene expression profiling , 2002, The Lancet.

[51]  T. Karn,et al.  Molecular classification of breast cancer patients by gene expression profiling * , 2001, The Journal of pathology.

[52]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[54]  J. Yuan,et al.  Polo-like kinase, a novel marker for cellular proliferation. , 1997, The American journal of pathology.

[55]  H. Ackermann,et al.  Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer , 1997, Oncogene.